AKT Inhibitors Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (ATP Competitive Inhibitors, Allosteric Inhibitors, Others), By Application (Cancer, Cardiovascular Disease, Autoimmune Disease, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Region  

AKT Inhibitors Market size was valued at US$ XXX million in 2023 and is expected to grow at a XX% CAGR from 2024 to 2030. AKT inhibitors bind to and inhibit the activity of AKT, which inhibits the PI3K/AKT signaling pathway, which leads to the inhibition of cell proliferation and the induction of apoptosis in tumor cells. The increasing incidence of cancer cases across the globe is expected to increase the demand and drive the market growth for AKT inhibitors. AKT inhibitors are promising therapeutic approaches for the treatment of cancer. Growing focus and investments by market players in the research and development of new AKT inhibitors with improved efficacy and lower toxicity are expected to boost the growth of the AKT inhibitors market over the forecast period. In addition, the advancement of technologies and enabling the development of more efficient and effective AKT inhibitors which is expected to have a positive impact on the growth of the AKT inhibitors market. However, the high cost of drug development and clinical trials along with the taking process are anticipated to restrain the market growth over the forecast period. In addition, side effects caused by the AKT inhibitors along with availability and high competition from other cancer treatments are expected to hold back the growth of the AKT inhibitors market over the forecast period. Moreover, increasing approvals by regulatory bodies on the pipeline drugs for clinical trials are expected to provide opportunities to market players in the development of AKT inhibitors and the growth of the market over the forecast period. For instance, In May 2019, the FDA approved Novartis Piqray, the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer. Geographically, the North America region held the major market share in 2022 and is expected to dominate the global AKT inhibitors market in the forecasted years.

AKT Inhibitors Market Key Developments:

• In May 2019, FDA approved Novartis Piqray, first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer.